Craniopharyngioma

Craniopharyngioma is a slow-growing, non-cancerous brain tumor located near the pituitary and hypothalamus. Despite its low incidence and classification as WHO grade I, its position in the saddle area complicates surgical intervention, leading to higher perioperative risks and poorer patient outcomes. Alfa Cytology is committed to pioneering new therapeutic approaches for craniopharyngioma treatment for our clients.

Introduction to Craniopharyngioma

Craniopharyngioma (CP) primarily manifests in two histological forms: adamantinomatous craniopharyngioma (ACP) and papillary craniopharyngioma (PCP). ACP is predominantly found in children and exhibits a bimodal age distribution, while PCP is more common in adults. The distinct genetic profiles of these tumors are characterized by specific mutations; ACP is often associated with activating mutations in the CTNNB1 gene (β-catenin), whereas PCP is linked to BRAF-V600E mutations.

Fig.1 Features of craniopharyngioma. (Müller, H. L., et al., 2019)

Therapeutic Development for Craniopharyngioma

The therapeutic landscape for craniopharyngioma has evolved significantly, with advances in surgical techniques, radiotherapy, and targeted therapies. Traditional management primarily involves surgical resection, which aims to achieve gross total resection (GTR) or subtotal resection (STR) followed by radiotherapy. While surgery can alleviate symptoms and reduce tumor burden, complete resection is often complicated by the tumor's invasive nature and proximity to critical neural structures.

We summarize here current treatments and relevant clinical trials for craniopharyngioma.

Our Services

At Alfa Cytology, we offer a comprehensive range of services designed to facilitate craniopharyngioma diagnostics and therapy development. Our team provides extensive support throughout the drug development process, from initial screening of compounds to detailed pharmacokinetic and pharmacodynamic studies.

Therapeutics Development

• Small Molecule Drug
• Radionuclide Therapy
• Therapeutic Antibody
• Peptide Drug
• Cell Therapy
• Gene Therapy
• Oncolytic Virotherapy
• Vaccine

Modeling Services

• Cell Line Development
• Organoids and Organ Chip Models
• Blood Brain Barrier Models
• Xenograft Models
• Syngeneic Models
• Virus-induced Models
• Transgenic Models
• Metastatic Models

Preclinical Research

• In Vitro Efficacy Evaluation
• In Vivo Efficacy Evaluation
• In Vitro ADME
• In Vivo PK
• Safety Assessment

Contact Us

For inquiries about our services or to discuss collaboration opportunities in the field of craniopharyngioma research, please reach out to Alfa Cytology. Our dedicated team is ready to assist you in advancing your therapeutic innovations. For further details, please reach out to our team for comprehensive information and assistance.

References

1. Müller, H.L.; et al. (2019). Craniopharyngioma[J]. Nat Rev Dis Primers. 5, 75.
2. Agosti E.; et al. (2024). Advancing Craniopharyngioma Management: A Systematic Review of Current Targeted Therapies and Future Perspectives[J]. International Journal of Molecular Sciences. 25(2): 723.